Over 10 Million Merchants Join Five Fortune Card Campaign on Alipay Platform to Further Engage With Consumers Ahead of CNY
21.1.2023 21:05:00 EET | Business Wire | Press release
Over 10 million brands and merchants in China joined Alipay’s signature annual Five Fortune Card Collection campaign for the 2023 Chinese New Year, ramping up digital efforts to attract and engage mobile-savvy consumers, as Chinese consumers gear up for the most important festival of the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230121005044/en/
A user trying to collect a fortune card by scanning the Chinese character “fu” with AR scan feature in Alipay app (Photo: Business Wire)
This year’s campaign, from January 10, 2023 to January 21, attracted more than 30,000 blue chip and emerging international and domestic brands and over 10 million small and micro business participants seeking to enhance their interaction with Chinese consumers in anticipation of the Spring Festival. This represented a nearly 30 times increase in the number of brands that participated in the campaign last year.
“As an open platform, Alipay is committed to opening up products and technologies to facilitate merchants’ digital transformation. We have also introduced Five Fortune Card IP-related resources to our partners,” said Yongming He, General Manager of the Alipay Ecosystem Development Business Unit and Vice President of Ant Group. “We are glad to see a growing number of brands and merchants participating in the Alipay Five Fortune Card Collection campaign to enhance engagement with users and improve operational efficiency by leveraging digital tools, including mini program and livestreaming, on the Alipay platform.”
Initially launched in 2015, Alipay's Five Fortune Card Collection campaign is an annual event before the Chinese New Year. Users collect digital fortune cards by using the Alipay app's AR scan feature and participating in merchant campaigns, among various ways to win a fortune card. These cards represent good wishes and can be converted into monetary rewards.
This year, for the first time, users can receive a limited-edition digital collectible featuring Chinese intangible cultural heritage, including shadow puppetry, paper-cut and copper sculpture, after successfully obtaining five fortune cards in the campaign.
Users can win a fortune card when they scan the red envelope QR code each time at the outlets of the 10 million participating merchants. They may also obtain cards by logging into Alipay mini programs or by watching livestreams of more than 30,000 participating brands on Alipay. Through these livestreams, brands distributed fortune cards to participants, introduced their products and services, and gave out preferential benefits to build connections with mobile-savvy Chinese consumers.
Merchants and brands have seen significant digital engagement through their participation in the Alipay campaign, with millions of views from livestreaming. On January 11, No. 1 Job Club, a job search service provider, saw 20 million visits to their livestreaming on Alipay platform. On the same day, Yunchongbao, a pet service provider, witnessed 50 million visits to their Alipay livestream. And on January 15, the NBA attracted over 12 million visits to their Alipay livestream which was moderated by several local basketball influencers. These numbers demonstrate the success of the campaign in attracting digital participation from merchants and brands, as reflected in the large livestream audience engagement on the Alipay platform.
Pop-Mart, a culture and entertainment company that is best known for art and collectible toys who introduced the idea of "blind box”, attracted three million visits to their Alipay mini-program six days into the campaign, with its transaction volume through the Alipay platform increasing 300% compared with that of last month.
About Alipay
In the evolving digital era, Alipay has transformed from a trusted payment tool to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operations on the Alipay platform, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than one billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230121005044/en/
Contact information
Media Enquiry
Bell Wang
yixing.wl@antgroup.com
+86 138 1038 5201
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom